BCR and acute lymphoblastic leukemia: XX-650–23 also demonstrated promising preclinical effectiveness when combined with the chemotherapy, dasatinib in pre-BCR+ ALL [183], overall uncovering new factors that influence sensitivity to targeted therapies in human pre-BCR+ ALL.